Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Regen BioPharma (RGBP) EPS (Weighted Average and Diluted) (2022 - 2025)

Regen BioPharma (RGBP) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.01 as the latest value for Q2 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 66.67% to -$0.01 in Q2 2025 year-over-year; TTM through Jun 2025 was -$0.17, a 17.73% increase, with the full-year FY2024 number at -$0.16, down 156.18% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.01 for Q2 2025 at Regen BioPharma, down from -$0.0 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.91 in Q3 2022 to a low of -$0.13 in Q4 2024.
  • A 4-year average of $0.18 and a median of -$0.03 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 225.0% in 2024, then surged 96.56% in 2025.
  • Regen BioPharma's EPS (Weighted Average and Diluted) stood at $0.43 in 2022, then tumbled by 109.28% to -$0.04 in 2023, then tumbled by 225.0% to -$0.13 in 2024, then soared by 92.31% to -$0.01 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's EPS (Weighted Average and Diluted) are -$0.01 (Q2 2025), -$0.0 (Q1 2025), and -$0.13 (Q4 2024).